The Analytical Development Scientist ADQC provides strong scientific judgment as well as hands-on laboratory expertise within the ADQC laboratory. This role focuses on driving day-to-day lab performance, ensuring consistent cGMP and regulatory compliance and data integrity standards. The role is responsible for executing analytical development activities supporting biologics programs from early phase to pivotal phase, regulatory submission, and commercialization. The incumbent will lead method development, optimization, qualification, validation, method transfer to internal and external laboratories, method lifecycle management, and ensure analytical readiness to support CMC milestones and regulatory submissions.
The ability to collaborate effectively with cross-functional teams and external partners in a highly regulated, fast-paced environment is crucial to this position.
Please note that some relocation assistance is available for this role.
This position does not supervise employees at this time. May supervise junior staff as the group expands.
Will have indirect supervisory level responsibilities with external partner/CDMO partnerships, and relationships.
Duties will be performed in normal office, laboratory and BSL2 laboratory environments.
Travel is not typical for this position.
Ability to regularly move up to 10 pounds. Specific vision abilities required by this individual include close vision, peripheral vision, and the ability to adjust focus. The employee will view a computer monitor for long periods of time.
The employer will make reasonable accommodations in compliance with the Americans with Disabilities Act of 1990.
This job description will be reviewed periodically as duties and responsibilities change with business necessity. Primary and additional duties and responsibilities are subject to modification.
SAB BIO is an Equal Opportunity Employer and prohibits discrimination and harassment of any kind. SAB BIO is committed to the principle of equal employment opportunity for all employees and does not discriminate based on race, religion, color, sex, gender identify, sexual orientation, age, non-disqualifying physical or mental disability, national origin, veteran status or any other legally protected status. EOE/AA/Vets

At SAB BIO, our mission is to dramatically redefine what it means to be diagnosed with type 1 diabetes (T1D) by developing a medicine to change the course of disease, not just treat symptoms.
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The Company was founded in 2014 and traded on Nasdaq (SABS) since 2021.
Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma.
To date, SAB BIO has conducted seven clinical trials that have dosed 700 individuals across multiple therapeutic areas. The safety and immunogenicity database for these trials shows zero patients with serum sickness or neutralizing anti-drug antibodies, which suggests an improved safety profile over other therapies.
SAB BIO’s lead product candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients.